In This Section

Program

Please note that this meeting will take place as an in-person event in Denver and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

FRIDAY, SEPTEMBER 19

SATURDAY, SEPTEMBER 20

SUNDAY, SEPTEMBER 21

Friday, September 19

REGISTRATION

3-5 p.m.

WELCOME AND OPENING Keynote

5-5:10 p.m. | Not CME-eligible

  • Ronald Bukanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania
  • Jung-Min Lee, National Cancer Institute, Bethesda, Maryland
  • Elizabeth M. Swisher, University of Washington, Seattle, Washington
  • Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts

Opening Keynote Address

5:10-5:45 p.m. | CME-eligible

  • George Coukos, Ludwig Institute for Cancer Research, Switzerland

Patient advocacy: Clinical trials and survivorship

5:45-6:45 p.m. | Not CME-eligible

  • Celeste Leigh Pearce, University of Michigan School of Public Health, Ann Arbor, Michigan
  • Kathryn Pennington, Alaska Women’s Cancer Care, Anchorage, Alaska
  • The biology of stress and resilience in ovarian cancer
    Susan K. Lutgendorf, University of Iowa, Iowa City, Iowa

Lightning Talks I

6:45-7:15 p.m. | CME-eligible

Opening Reception + Poster Session A

7:15–8:45 p.m.

Saturday, September 20

Continental Breakfast

7-8 a.m.

Networking Roundtables

7-8 a.m.

Plenary Session 1: Tumor initiation

8-10:05 a.m. | CME-eligible

  • Lan G. Coffman, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  • Discovery of fitness fingerprints and flower monoclonal ab therapy in ovarian cancer
    Rajan Gogna, Virginia Commonwealth University, Richmond, Virginia
  • Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma
    Tanjina Kader, Harvard Medical School, Boston, Massachusetts
  • Hui Shen, Van Andel Institute, Grand Rapids, Michigan

Short talks selected from proffered abstracts

Break

10:05-10:25 a.m.

Plenary Session 2: Tumor heterogeneity

10:25 a.m.-12:05 p.m. | CME-eligible

  • Rugang Zhang, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • Oladapo Yeku, Massachusetts General Hospital, Boston, Massachusetts
  • Ronald Bukanovich, Magee-Womens Research Institute, Pittsburgh, Pennsylvania

Short talks selected from proffered abstracts

Lunch on own

12:05-1:45 p.m.

Plenary Session 3: Tumor immunology (biology)

1:45–3:20 p.m. | CME-eligible

  • Sandra Cascio, University of Pittsburgh, Pittsburgh, Pennsylvania
  • Enhancing T cell metabolic fitness for ovarian cancer immunotherapy
    Juan Cubillos-Ruiz, Weill Cornell Medicine, New York, New York

Short talks selected from proffered abstracts

Break

3:20-3:40 p.m.

Proffered Talks

3:40-4:40 p.m. | CME-eligible

Break

4:40-5 p.m.

Plenary Session 4: Precision therapy

5-6:35 p.m. | CME-eligible

  • Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer
    Mary Margaret Mullen, Washington University School of Medicine, St. Louis, Missouri
  • Elizabeth M. Swisher, University of Washington, Seattle, Washington
  • Susana Banerjee, The Royal Marsden Hospital, London, United Kingdom

Short talks selected from proffered abstracts

Lightning Talks II

6:35-7:00 p.m. | CME-eligible

Reception + Poster Session B

7-8:30 p.m.

Sunday, September 21

Continental Breakfast

7-8 a.m.

Plenary Session 5: Tumor immunology

8-9:25 a.m. | Not CME-eligible

  • Claire F. Friedman, Memorial Sloan Kettering Cancer Center, New York, New York
  • Dendritic cells and modulation of TME in the therapy of ovarian cancer
    Pawel Kalinski, Roswell Park Comprehensive Cancer Center, Buffalo, New York
  • Branden S. Moriarity, University of Minnesota, Minneapolis, Minnesota,

Short talk selected from proffered abstracts

Break

9:25-9:55 a.m.

Plenary Session 6: Genomics

9:55-11:25 a.m. | CME-eligible

  • Neil Johnson, Fox Chase Cancer Center, Philadelphia, Pennsylvania
  • Jung-Min Lee, National Cancer Institute, Bethesda, Maryland

Short talk selected from proffered abstracts

Break

11:25-11:40 a.m.

Keynote 2

11:40 a.m.-12:15 p.m. | CME-eligible

  • Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Plenary Session 7: Pathology

12:15-1:35 p.m. | CME-eligible

  • AI-powered discovery of digital biomarkers in ovarian cancer
    Heba Sailem, King’s College London, London, United Kingdom
  • Implementing AI-driven support for improved ultrasound diagnosis of ovarian tumors
    Elisabeth Epstein, Karolinska Institute, Stockholm, Sweden

Closing Remarks + Departure

1:35 p.m.